Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00224068
Status:
COMPLETED
Last Update Posted:
2012-03-02
First Post:
2005-09-13
Brief Title:
Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy
Sponsor:
Watson Pharmaceuticals
Organization:
Watson Pharmaceuticals
Study Overview
Official Title:
A Multicenter Randomized Controlled Prospective Trial of the Safety and Efficacy of Ferrlecit in Anemic Cancer Patients Who Are Receiving Acute Chemotherapy and Epoetin as Compared to Oral Iron and No Treatment
Status:
COMPLETED
Status Verified Date:
2012-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study evaluates the safety and efficacy of Ferrlecit ferric gluconate a form of intravenous iron or ferrous sulfate a form of oral iron in improving the response to epoetin alfa among anemic cancer patients receiving chemotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None